TABLE 1.

Patient Characteristics

Characteristic	RP (n = 1,018 [51.2%])	PORT (n = 593 [29.4%])	RT (n = 394 [19.4%])
Site (n)
University of Michigan	372 (36.5%)	264 (44.5%)	192 (48.7%)
University of California San Francisco	109 (10.7%)	82 (13.8%)	81 (20.6%)
UCLA	537 (52.8%)	247 (41.7%)	121 (30.7%)
Age (y)
Median	68 (IQR, 63–73)	70 (IQR, 65–74)	72 (IQR, 67–77)
No. missing	0	0	0
PSA at scan (ng/mL)
Median	0.78 (IQR, 0.4–2.3)	1.58 (IQR, 0.7–3.3)	5.7 (IQR, 3.4–10.9)
No. missing	0	0	0
PSA nadir (ng/mL)
Median	0.2 (IQR, <0.1–0.3)	<0.1 (IQR, <0.1–0.7)	0.3 (IQR, 0.1–0.8)
No. missing	458	212	46
Initial PSA at diagnosis (ng/mL)
Median	7 (IQR, 5.1–11.3)	6.4 (IQR, 4.7–10.2)	7.6 (IQR, 5.4–7.6)
No. missing	651	336	209
T-stage (RP)
Median	8 (IQR, 6–10)	7 (IQR, 6–10)	NA
No. missing	230	433
Clinical T-stage
Median	3 (IQR, 3–4)	3 (IQR, 3–4)	3 (IQR, 3–6)
No. missing	19	433	126
Gleason grade group (RP)
Median	3 (IQR, 2–5)	3 (IQR, 2–5)	NA
No. missing	19	5
Gleason grade group at biopsy
Median	3 (IQR, 2–4)	3 (IQR, 2–4)	3 (IQR, 2–4)
No. missing	727	403	5
PSMA injected dose (MBq)
Median	200 (IQR, 185--229)	204 (IQR, 185--229)	215 (IQR, 185--233)
No. missing	4	3	1
Treatment-to-scan interval (mo)
Median	40.2 (IQR, 8.4–104.0)	82.3 (IQR, 48.4–130.6)	75.4 (IQR, 40.3–122.5)
No. missing	23	15	24

NA = not applicable.

T-stage nomenclature: T1 = 1, T1a = 2, T1b = 3, T1c = 4, T2 = 5, T2a = 6, T2b = 7, T2c = 8, T3 = 9, T3a = 10, T3b = 11, T4 = 12.